Evidence map›Paper›PMID 35315211›Full record

ArticleInternational wound journal2022

Dual efficacy of Fasudil at improvement of survival and reinnervation of flap through RhoA/ROCK/PI3K/Akt pathway.

Hai Wang, Fang Fang, Shaofeng Chen, Xing Jing, Yuehong Zhuang, Yun Xie

Open access · goldAbstract read
In one paragraph

Article in International wound journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Augmentation of functional recovery viaJournal of orthopaedic translation · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hai WangOrthopedic Department, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Fang FangDepartment of pharmacology, Fujian Medical University, Fuzhou, China.
Shaofeng ChenKey Laboratory of Brain Aging and Neurodegenerative Diseases, Institute of Clinical Applied Anatomy, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Xing JingKey Laboratory of Brain Aging and Neurodegenerative Diseases, Institute of Clinical Applied Anatomy, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Yuehong ZhuangKey Laboratory of Brain Aging and Neurodegenerative Diseases, Institute of Clinical Applied Anatomy, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.ORCID https://orcid.org/0000-0003-3997-7663
Yun XieOrthopedic Department, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Fujian Medical University · CN

Funding

Fujian Natural Science Foundations 2020J01625Fujian Natural Science Foundations 2021J01241Fujian Natural Science Foundations 2021J01666
6 · The paper itself

Abstract

Fasudil is reported to be effective at protecting against ischaemic diseases, and at augmenting axon growth. In this study, we aim to evaluate its efficacy in promoting flap survival and reinnervation. Ninety-two Institute of Cancer Research (ICR) mice were used and divided into the control, Fasudil, LY294002, Fasudil+LY294002 groups, receiving a daily intraperitoneal injection of normal saline, Fasudil (10 mg/kg), LY294002 (5 mg/kg), and Fasudil (10 mg/kg) + LY294002 (5 mg/kg), respectively. On days 0 and 5, the blood perfusion and diameter of the iliolumbar artery in the pedicle of the flaps in the four groups were evaluated using laser speckling contrast imaging (LSCI). On day 5, the flaps were photographed and the necrosis rate of the flaps was calculated using Photoshop CS6. In addition, tissues were harvested from the flaps and divided into two parts. One part underwent routine cryosection and immunofluorescent staining using the antibody against CD31 for evaluation of the microvascular density in the four groups. In the other part, the expression of RhoA, ROCK1+2, p-CPI-17, p-MYPT, p-PTEN, p-PI3K, p-Akt, and vascular endothelial growth factor (VEGF) within the flaps were determined using western blotting. Moreover, at days 0, 7, 15, and 30 after flap surgery, the axons within the flaps were evaluated using immunofluorescent staining with the antibody against Neurofilament-200. It turned out that the necrosis rate was (24.4 ± 7.7)%, (5.2 ± 1.6)%, (29.8 ± 4.2)%, and (30.9 ± 7.1)%, respectively, in the control, Fasudil, LY294002, LY294002+Fasudil groups. There was a significant reduction in the necrosis rate of the flaps in the Fasudil group (P < .001). The LSCI and immunofluorescent staining demonstrated that Fasudil could significantly expand the diameter of the iliolumbar artery in the pedicle, boost the overall blood perfusion, and increase the microvascular density of the flaps in the Fasudil group (P < .05), which could all be abolished by PI3K inhibitor LY294002. On day 5, the expression of p-CPI-17, p-MYPT, and p-PTEN were downregulated, whereas pPI3K, p-Akt, and VEGF were upregulated in the Fasudil group (P < .001). As for reinnervation, Neurofilament-200 fluorescent staining revealed that at days 15 and 30 after flap harvest, only in the Fasudil group could new axons be observed. It can be concluded that Fasudil could simultaneously improve the survival and axon growth after flap harvest, a dual efficacy achieved by inhibition of the RhoA/ROCK pathway, which in turn activates /PI3K/AKT pathway.

Indexed as

Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnimalsMiceNecrosisVascular Endothelial Growth Factor A1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinefasudilPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor AFasudilflapPI3K/AktPTENRhoA/ROCK

Identifiers

PMID35315211
PMCPMC9705174
OpenAlexW4220967625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.